{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:57:21Z","timestamp":1789185441168,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T00:00:00Z","timestamp":1069286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:sc>objective<\/jats:sc>\u2002<\/jats:bold> Recombinant hGH treatment may alter thyroid hormone metabolism and we have recently reported that 50% of patients with GH deficiency (GHD) due to organic lesions, previously not treated with thyroxine, developed hypothyroidism during treatment with recombinant human GH (rhGH). These results prompted us to evaluate the impact of rhGH treatment on thyroid function in children with GHD.<\/jats:p><jats:p><jats:bold><jats:sc>design<\/jats:sc>\u2002<\/jats:bold> Open study of GH treatment up to 12\u00a0months. Investigations were performed at baseline, and after 6 and 12\u00a0months of GH therapy.<\/jats:p><jats:p><jats:bold><jats:sc>measurement and study subjects<\/jats:sc>\u2002<\/jats:bold> Serum TSH, FT4, FT3, AbTg and AbTPO, IGF\u2010I, height and weight, were evaluated in 20 euthyroid children (group A) with idiopathic isolated GHD and in six children (group B) with multiple pituitary hormone deficiencies (MPHD) due to organic lesions. Among the latter, four already had central hypothyroidism and were on adequate LT4 replacement therapy, while two were euthyroid at the beginning of the study.<\/jats:p><jats:p><jats:bold><jats:sc>results<\/jats:sc>\u2002<\/jats:bold> Serum IGF\u2010I levels normalized in all patients. In both groups, a significant reduction in FT4 levels (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b701) occurred during rhGH therapy. No patient in group A had FT4 values into the hypothyroid range, while in four of six patients in group B, fell FT4 levels into the hypothyroid range during rhGH. In particular, the two euthyroid children developed central hypothyroidism during rhGH treatment, and their height velocities did not normalize until the achievement of euthyroidism through appropriate LT4 substitution. No variation in serum FT3 and TSH levels was recorded in either groups.<\/jats:p><jats:p><jats:bold><jats:sc>conclusion<\/jats:sc>\u2002<\/jats:bold> Contrary to that observed in patients with MPHD, rhGH replacement therapy does not induce central hypothyroidism in children with idiopathic isolated GHD, further supporting the view that in children with MPHD, as in adults, GHD masks the presence of central hypothyroidism. Slow growth (in spite of adequate rhGH substitution and normal IGF\u2010I levels) is an important clinical marker of central hypothyroidism, therefore a strict monitoring of thyroid function is mandatory in treated children with MPHD.<\/jats:p>","DOI":"10.1046\/j.1365-2265.2003.01892.x","type":"journal-article","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:47:46Z","timestamp":1069386466000},"page":"806-810","source":"Crossref","is-referenced-by-count":51,"title":["Recombinant hGH replacement therapy and the hypothalamus\u2013pituitary\u2013thyroid axis in children with GH deficiency: when should we be concerned about the occurrence of central hypothyroidism?"],"prefix":"10.1111","volume":"59","author":[{"given":"Claudia","family":"Giavoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Porretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cappiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina L.","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Travaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Epaminonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Arosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Beck\u2010Peccoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,11,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.617439.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1051\/rnd:19890401"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1979.tb05028.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-52-2-324"},{"key":"e_1_2_6_6_1","first-page":"13","article-title":"The effect of hGH on hypotalamic\u2013pituitary\u2013thyroid function in patients with pituitary dwarfism","volume":"93","author":"Demura R.","year":"1980","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.3.924"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-67-5-1111"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-69-6-1127"},{"issue":"1","key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000182572","article-title":"Thyroid function during growth hormone therapy","volume":"38","author":"J\u00f8rgensen J.O.L.","year":"1992","journal-title":"Hormone Research"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb01826.x"},{"key":"e_1_2_6_12_1","first-page":"515","article-title":"Effects of insulin\u2010like growth factor I on the thyroid axis in patients with Laron\u2010type dwarfism and healthy subjects","volume":"127","author":"Klinger B.","year":"1992","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-40-4-612"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.4.950"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81191-6"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-28-5-603"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81190-4"},{"key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/jcem.87.5.8479","article-title":"Recombinant human GH replacement therapy and thyroid function in a large group of adult GH\u2010deficient patients: when does L\u2010T4 therapy become mandatory?","volume":"87","author":"Porretti S.","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1542\/peds.51.4.668","article-title":"Abnormal thyroxine metabolism in hyposomatotrophic dwarfism and inhibition of responsiveness to TRH during GH therapy","volume":"51","author":"Porter B.A.","year":"1973","journal-title":"Pediatrics"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.01071.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2003.16.1.35"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198101000-00002"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.1.320"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(76)90155-4"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912283212605"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-45-2-324"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.10.3493"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2003.01892.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2003.01892.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.2003.01892.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T16:41:36Z","timestamp":1697215296000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.2003.01892.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,20]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1046\/j.1365-2265.2003.01892.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01892.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,20]]}}}